View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 2, 2019updated 03 Apr 2019 7:30am

J&J concludes $3.4bn Auris Health acquisition

Johnson & Johnson (J&J) subsidiary Ethicon has closed a $3.4bn acquisition of surgical robotics developer Auris Health.

Johnson & Johnson (J&J) subsidiary Ethicon has closed a $3.4bn acquisition of surgical robotics developer Auris Health.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Under the deal, Auris Health is eligible for up to $2.35bn in additional contingent payments, depending on the achievement of select predetermined milestones.

The companies first signed the definitive agreement in February this year. J&J plans to leverage Auris Health’s Monarch Platform to expand its digital portfolio across a variety of surgical specialities. The system is currently used in lung diagnostic and therapeutic procedures.

J&J medical devices executive vice-president and worldwide chairman Ashley McEvoy said: “We are focused on building a connected, data-driven digital ecosystem that pairs our market-leading surgical solutions with advanced technologies to improve the patient experience.

“The passionate team and differentiated innovation from Auris will help us amplify the power of digital surgery to address unmet clinical needs.”

“The passionate team and differentiated innovation from Auris will help us amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer intervention.”

The healthcare giant added that Auris Health’s platform complements robotic technologies that are being developed for general surgery applications by Verb Surgical, a joint venture (JV) between J&J and Verily.

The platform will also support orthopaedics robotic technologies by Orthotaxy, which was acquired by J&J in February last year.

J&J has completed a sale of its advanced sterilisation products (ASP) business to Fortive for a total consideration of $2.8bn. This deal comprised $2.7bn in cash proceeds and $0.1bn in retained net receivables. Fortive made a binding offer to buy the ASP business in June last year.

ASP is focused on delivering capital, consumables and software solutions for low-temperature terminal sterilisation and high-level disinfection of reusable surgical instruments to prevent hospital-acquired infections.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network